AviadoBio Presents Dose-Dependent CSF Progranulin Data from Phase 1/2 ASPIRE-FTD Trial
AviadoBio has presented preliminary Phase 1/2 ASPIRE-FTD data for AVB-101, its gene therapy for FTD-GRN, showing dose-dependent increases in CSF progranulin across four cohorts, with 12-week rises of 36% and 90% over baseline in the third and fourth. The trial has dosed 17 patients, with no serious adverse events related to treatment and no immunosuppression required.